Viral-vectored vaccines to control pathogenic filoviruses

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

For more than 35 years the filoviruses, Marburg virus and Ebola virus, have caused sporadic outbreaks of hemorrhagic fever that result in severe and often fatal disease in humans and nonhuman primates. Pathogenic Marburg and Ebola viruses are endemic in resource-poor regions in Central Africa and are also of concern as they have the potential for deliberate misuse. Although no vaccines or antiviral drugs for filoviruses are currently available for human use, remarkable progress has been made in developing candidate preventive vaccines against Marburg and Ebola viruses in nonhuman primate models. Most of these vaccines are based on viral vectors including recombinant adenoviruses, alphaviruses, paramyxoviruses, and rhabdoviruses. Because of the remote geographic locations of most filovirus outbreaks, a single-injection vaccine is an important goal in vaccine development. Among the prospective viral-vectored vaccines that have demonstrated efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant vesicular stomatitis virus (rVSV), were shown to confer complete protection to nonhuman primates when administered as a single injection. Notably, the rVSV-based vaccines have also shown utility when used as postexposure treatments for filovirus infections.

Original languageEnglish (US)
Title of host publicationNovel Technologies for Vaccine Development
PublisherSpringer-Verlag Wien
Pages33-60
Number of pages28
Volume9783709118184
ISBN (Print)9783709118184, 3709118174, 9783709118177
DOIs
StatePublished - Jul 1 2014

Fingerprint

Viral Vaccines
Marburgvirus
Vaccines
Ebolavirus
Primates
Vesicular Stomatitis
Adenoviridae
Disease Outbreaks
Fever
Rhabdoviridae
Alphavirus
Viruses
Central Africa
Geographic Locations
Injections
Antiviral Agents
Infection

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Mire, C., & Geisbert, T. (2014). Viral-vectored vaccines to control pathogenic filoviruses. In Novel Technologies for Vaccine Development (Vol. 9783709118184, pp. 33-60). Springer-Verlag Wien. https://doi.org/10.1007/978-3-7091-1818-4_2

Viral-vectored vaccines to control pathogenic filoviruses. / Mire, Chad; Geisbert, Thomas.

Novel Technologies for Vaccine Development. Vol. 9783709118184 Springer-Verlag Wien, 2014. p. 33-60.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mire, C & Geisbert, T 2014, Viral-vectored vaccines to control pathogenic filoviruses. in Novel Technologies for Vaccine Development. vol. 9783709118184, Springer-Verlag Wien, pp. 33-60. https://doi.org/10.1007/978-3-7091-1818-4_2
Mire C, Geisbert T. Viral-vectored vaccines to control pathogenic filoviruses. In Novel Technologies for Vaccine Development. Vol. 9783709118184. Springer-Verlag Wien. 2014. p. 33-60 https://doi.org/10.1007/978-3-7091-1818-4_2
Mire, Chad ; Geisbert, Thomas. / Viral-vectored vaccines to control pathogenic filoviruses. Novel Technologies for Vaccine Development. Vol. 9783709118184 Springer-Verlag Wien, 2014. pp. 33-60
@inbook{4d591625580f484696b1bb4bdd348fc2,
title = "Viral-vectored vaccines to control pathogenic filoviruses",
abstract = "For more than 35 years the filoviruses, Marburg virus and Ebola virus, have caused sporadic outbreaks of hemorrhagic fever that result in severe and often fatal disease in humans and nonhuman primates. Pathogenic Marburg and Ebola viruses are endemic in resource-poor regions in Central Africa and are also of concern as they have the potential for deliberate misuse. Although no vaccines or antiviral drugs for filoviruses are currently available for human use, remarkable progress has been made in developing candidate preventive vaccines against Marburg and Ebola viruses in nonhuman primate models. Most of these vaccines are based on viral vectors including recombinant adenoviruses, alphaviruses, paramyxoviruses, and rhabdoviruses. Because of the remote geographic locations of most filovirus outbreaks, a single-injection vaccine is an important goal in vaccine development. Among the prospective viral-vectored vaccines that have demonstrated efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant vesicular stomatitis virus (rVSV), were shown to confer complete protection to nonhuman primates when administered as a single injection. Notably, the rVSV-based vaccines have also shown utility when used as postexposure treatments for filovirus infections.",
author = "Chad Mire and Thomas Geisbert",
year = "2014",
month = "7",
day = "1",
doi = "10.1007/978-3-7091-1818-4_2",
language = "English (US)",
isbn = "9783709118184",
volume = "9783709118184",
pages = "33--60",
booktitle = "Novel Technologies for Vaccine Development",
publisher = "Springer-Verlag Wien",

}

TY - CHAP

T1 - Viral-vectored vaccines to control pathogenic filoviruses

AU - Mire, Chad

AU - Geisbert, Thomas

PY - 2014/7/1

Y1 - 2014/7/1

N2 - For more than 35 years the filoviruses, Marburg virus and Ebola virus, have caused sporadic outbreaks of hemorrhagic fever that result in severe and often fatal disease in humans and nonhuman primates. Pathogenic Marburg and Ebola viruses are endemic in resource-poor regions in Central Africa and are also of concern as they have the potential for deliberate misuse. Although no vaccines or antiviral drugs for filoviruses are currently available for human use, remarkable progress has been made in developing candidate preventive vaccines against Marburg and Ebola viruses in nonhuman primate models. Most of these vaccines are based on viral vectors including recombinant adenoviruses, alphaviruses, paramyxoviruses, and rhabdoviruses. Because of the remote geographic locations of most filovirus outbreaks, a single-injection vaccine is an important goal in vaccine development. Among the prospective viral-vectored vaccines that have demonstrated efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant vesicular stomatitis virus (rVSV), were shown to confer complete protection to nonhuman primates when administered as a single injection. Notably, the rVSV-based vaccines have also shown utility when used as postexposure treatments for filovirus infections.

AB - For more than 35 years the filoviruses, Marburg virus and Ebola virus, have caused sporadic outbreaks of hemorrhagic fever that result in severe and often fatal disease in humans and nonhuman primates. Pathogenic Marburg and Ebola viruses are endemic in resource-poor regions in Central Africa and are also of concern as they have the potential for deliberate misuse. Although no vaccines or antiviral drugs for filoviruses are currently available for human use, remarkable progress has been made in developing candidate preventive vaccines against Marburg and Ebola viruses in nonhuman primate models. Most of these vaccines are based on viral vectors including recombinant adenoviruses, alphaviruses, paramyxoviruses, and rhabdoviruses. Because of the remote geographic locations of most filovirus outbreaks, a single-injection vaccine is an important goal in vaccine development. Among the prospective viral-vectored vaccines that have demonstrated efficacy in nonhuman primate models of filoviral hemorrhagic fever, two candidates, one based on a replication-defective adenovirus serotype 5 and the other on a recombinant vesicular stomatitis virus (rVSV), were shown to confer complete protection to nonhuman primates when administered as a single injection. Notably, the rVSV-based vaccines have also shown utility when used as postexposure treatments for filovirus infections.

UR - http://www.scopus.com/inward/record.url?scp=84930832471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930832471&partnerID=8YFLogxK

U2 - 10.1007/978-3-7091-1818-4_2

DO - 10.1007/978-3-7091-1818-4_2

M3 - Chapter

SN - 9783709118184

SN - 3709118174

SN - 9783709118177

VL - 9783709118184

SP - 33

EP - 60

BT - Novel Technologies for Vaccine Development

PB - Springer-Verlag Wien

ER -